Lepodisaran is a silencing RNA compound that targets apo(a) messenger RNA. It is being tested in a Phase 3 cardiovascular outcomes trial (ACCLAIM-Lp(a); NCT06292013 (currently recruiting)) with an anticipated study completion date of March 2029. Other Lp(a)-specific lowering drugs in the pipeline: There are several additional compounds that are in earlier stages of development.36 These include zerlasiran, another siRNA compound against apo(a) mRNA (Phase 2 completed; up to 96% Lp(a) lowering), and a small molecule (muvalaplin) that disrupts Lp(a) formation and is in Phase 2 (NCT05563246), with up to 65% Lp(a) reduction observed in Phase 1. 14
RkJQdWJsaXNoZXIy MjI2NjI=